Careful, Pfizer May Be Mainlining Viagra

Big Pharma has been a great place to put money to work over the last year. Many names have taken a breather since March and are now starting to come out of their slumber. Merck, $MRK, broke out of its blue box consolidation in mid June and is now running hard to the break out target at 48, as shown in the chart below. The Relative Strength Index (RSI) over 75 is showing an overbought condition so a consolidation or pullback in that move is likely in the near term. But this

Merck, $MRK

just shows the potential. The real jewel is just getting the testosterone flowing for a prolonged extension higher. Pfizer, $PFE, is just starting to poke its head out of the blue box for a money shot higher. And if it washed down the full contents of the box of little blue pills, the trip higher will most certainly last more than 4 hours. It has room on the RSI for a prolonged extension with a target on the rise to 29, making the market cap a full 26% larger than it is today. Quite an enhancement.

Pfizer, $PFE

If you like what you see above sign up for deeper analysis and trading strategy by using the Get Premium button above. As always you can see details of individual charts and more on my StockTwits page.

The information in this blog post represents my own opinions and does not contain a recommendation for any particular security or investment. I or my affiliates may hold positions or other interests in securities mentioned in the Blog, please see my Disclaimer page for my full disclaimer.

blog comments powered by Disqus
Dragonfly Caps Blog